Brian Kim

Brian Kim

Company: Washington University School of Medicine & Nuogen Pharma

Job title: Associate Professor & Founder/Chief Scientific Officer

Bio:

Dr. Brian S. Kim’s laboratory focuses on innate immune mechanisms that underlie skin inflammation and the sensation of itch. He identified previously unrecognized contributions of group 2 innate lymphoid cells (ILC2s) and basophils to the pathogenesis of atopic dermatitis (AD) in both mice and humans. These cells have emerged as critical sources of the type 2 cytokines IL-4, IL-5, and IL-13, which are now among the most important targets for biologic therapy in AD and other allergic disorders. More recently, the Kim Lab was the first to identify functionality of IL-4/13 and Janus kinases (JAKs) in sensory neurons as master regulators of chronic itch. These studies have immediate clinical implications as type 2 cytokine and JAK blockade have emerged as some of the most efficacious therapeutics in AD. His research on the immune regulation of AD and itch has led to awards and funding from the NIH, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, and the American Society for Clinical Investigation.

Seminars:

Afternoon Discussion Session 3:30 pm

What are the various forms of administration for JAK inhibitors? How can we balance exposure/safety with clinical response through different routes of administration? Pros and cons of oral, dermal and inhaled delivery on pharmacokinetics, pharmacodynamics and safety profile Formulation challenges and opportunities of different dosage forms of JAK inhibitorsRead more

day: Day One

Live Discussion & Question Time 2:30 pm

What are the clinical cross-learnings for JAK inhibitor application across both blood-related disorders and immune-mediated diseases? How can we refine clinical trial protocols to include clinically meaningful biomarkers with improved predictability of patient response and clinically meaningful endpoints? In what clinical indications do effective combination regimens that include JAK inhibitors play a role and how…Read more

day: Day One

Development of JAK Inhibitors for Chronic Itch 2:10 pm

Target identification in new tissue Proving mechanisms of action Developing novel route of deliveryRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.